%0 Journal Article %A Scott G Williams %A Han Aw Yeang %A Catherine Mitchell %A Franco Caramia %A David J Byrne %A Stephen B Fox %A Sue Haupt %A Paul J Neeson %A Ygal Haupt %A Simon P Keam %T Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype %D 2020 %R 10.1101/2020.06.01.20115345 %J medRxiv %P 2020.06.01.20115345 %X Understanding the drivers of recurrence in aggressive prostate cancer requires detailed molecular and genomic understanding in order to aid therapeutic interventions. Here we present a case study of a male in 70s with high-grade clinically-localised acinar adenocarcinoma treated with definitive hormone therapy and radiotherapy. The patient progressed rapidly with rising PSA and succumbed without metastasis 52 months after diagnosis. We provide here a description of histological, transcriptional, proteomic, immunological, and genomic features associated with this disease – identifying hallmarks of canonical neuroendocrine PC disease and other novel molecular features.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Peter Mac Foundation, the Victorian Cancer Agency, a Prostate Cancer Foundation USA (Creativity award), Cancer Council Victoria (Grant-In-Aid) and an NHMRC Program Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The participant provided consent covering tissue research as part of a prospective tissue col-lection study for prostate radiobiology research approved by the Human Research Ethics Committee at the Peter MacCallum Cancer Centre (PMCC; HREC approvals 10/68, 13/167, 19/32).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request. %U https://www.medrxiv.org/content/medrxiv/early/2020/06/02/2020.06.01.20115345.full.pdf